

FOR IMMEDIATE RELEASE

June 1st 2015 - The OsteoArthritis Centers of America, (Florence, South Carolina) and Gensco Laboratories – A Specialty Pharmaceutical Company (Miami Florida) are pleased to announce a collaborative research agreement to enhance OA Centers of America’s proprietary algorithm for the treatment of pain conditions.

The OsteoArthritis Centers of America will incorporate Gensco’s patented Transdermal products (SpeedGel Rx® and LiDORx®) as an option to demonstrate improved patient outcomes and economic value of treating specific types of pain with transdermal technology. The results will be published to share and improve treatment approaches globally.

Carlos Alfaras – Gensco President and CEO – “There is a clear need for a non-narcotic pain control option for patients. We are very excited to collaborate with OA Centers of America a proven leader in treating patients with osteoarthritis and musculoskeletal pain. Their strong commitment to developing outcomes driven clinical programs has provided a perfect opportunity to work together to improve patient care.”

About OsteoArthritis Centers of America

OsteoArthritis Centers of America is one the nation’s largest single brands associated with the treatment of osteoarthritis and other musculoskeletal conditions. They have created outcomes driven clinical programs focused on non-surgical, FDA approved treatments for chronic pain in knees, hips, shoulders, and back, peripheral neuropathies, and other conditions. The company was founded in 1998, in order to develop clinical services and education programs for medical practices, which can be replicated and measured. Previously published work includes a peer reviewed pragmatic outcomes paper analyzing the results of the company’s proprietary OsteoArthritis knee program. For more information visit our website at www.oacenters.com

About Gensco Laboratories – A Specialty Pharmaceutical Company

Gensco Laboratories is a FDA regulated, licensed Pharmaceutical manufacturer focusing on the research, development, and marketing of transdermal prescription products. As an innovator of pharmaceutical products and the development of patented drug delivery systems, we are dedicated to the continual pursuit of novel and effective therapies that improve health.

For more information visit our website at www.genscolabs.com